Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

FACTORS OF SPREAD OF VIRAL HEPATITIS A INFECTION AND PREVENTIVE MEASURES

Azizova F.L.
Aleuyetdinova A.B.
Tashkent State Medical University, School of Public Health

Abstract
Particular attention is paid to the role of waterborne transmission associated with contaminated drinking water, outdated water supply and sewage systems, and insufficient sanitary control. In addition, socio-demographic factors such as population density, internal and external migration, household crowding, and low levels of health awareness are considered as important determinants of disease transmission. Environmental problems, including water scarcity and ecological degradation, are also examined as indirect factors influencing the epidemiological situation.The research is based on a comprehensive analysis of epidemiological surveillance data, official healthcare statistics, and published scientific sources.

Keywords: viral hepatitis A, epidemiology, transmission factors, preventive measures, waterborne infections, public health.

Introduction
Hepatitis A is a common viral infection worldwide that is transmitted via the fecal-oral route. The incidence of infection in the United States decreased by more than 90% after an effective vaccine was introduced, but the number of cases has been increasing because of large community outbreaks in unimmunized individuals. Classic symptoms include fever, malaise, dark urine, and jaundice and are more common in older children and adults. People are most infectious 14 days before and seven days after the development of jaundice. Diagnosis of acute

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas
Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

infection requires the use of serologic testing for immunoglobulin M anti-hepatitis A antibodies. The disease is usually self-limited, supportive care is often sufficient for treatment, and chronic infection or chronic liver disease does not occur. Routine hepatitis A immunization is recommended in children 12 to 23 months of age. Immunization is also recommended for individuals at high risk of contracting the infection, such as persons who use illegal drugs, those who travel to areas endemic for hepatitis A, incarcerated populations, and persons at high risk of complications from hepatitis A, such as those with chronic liver disease or HIV infection. The vaccine is usually recommended for pre- and postexposure prophylaxis, but immune globulin can be used in patients who are too young to be vaccinated or if the vaccine is contraindicated[1].

Viral hepatitis constitutes a substantial global public health challenge. The etiological agents, referred to as hepatitis viruses, are primarily categorized into five types: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). Among the various preventive strategies, vaccination is widely acknowledged as the most cost-effective and efficient method for controlling viral hepatitis and its related hepatic complications. To date, numerous countries have initiated extensive vaccination programs targeting hepatitis A and hepatitis B. Advances in biotechnology have facilitated substantial progress in vaccine formulation design, the development of innovative adjuvants, and the utilization of novel vectors. However, significant challenges persist, including inadequate vaccination coverage, inconsistent immune responses among vulnerable populations, and concerns regarding vaccine safety. This article presents a systematic review of recent advancements, the current status of vaccination efforts, and ongoing challenges associated with hepatitis vaccines, with the objective of providing critical insights to support the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030 [8].

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas
Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

The hepatitis A virus (HAV) is a leading cause of acute viral hepatitis worldwide. It is transmitted mainly by direct contact with patients who have been infected or by ingesting contaminated water or food. The virus is endemic in low-income countries where sanitary and sociodemographic conditions are poor. Paradoxically, improving sanitary conditions in these countries, which reduces the incidence of HAV infections, can lead to more severe disease in susceptible adults. The populations of developed countries are highly susceptible to HAV, and large outbreaks can occur when the virus is spread by globalization and by increased travel and movement of foodstuffs. Most of these outbreaks occur among high-risk groups: travellers, men who have sex with men, people who use substances, and people facing homelessness. Hepatitis A infections can be prevented by vaccination; safe and effective vaccines have been available for decades. Several countries have successfully introduced universal mass vaccination for children, but high-risk groups in high-income countries remain insufficiently protected. The development of HAV antivirals may be important to control HAV outbreaks in developed countries where a universal vaccination programme is not recommended [2].

Hepatitis A is an acute infection of the liver, which is mostly asymptomatic in children and increases the severity with age. Although in most patients the infection resolves completely, in a few of them it may follow a prolonged or relapsed course or even a fulminant form. The reason for these different outcomes is unknown, but it is generally accepted that host factors such as the immunological status, age and the occurrence of underlaying hepatic diseases are the main determinants of the severity. However, it cannot be ruled out that some virus traits may also contribute to the severe clinical outcomes. In this review, we will analyze which genetic determinants of the virus may determine virulence, in the context of a paradigmatic virus in terms of its genomic, molecular, replicative, and evolutionary features [3].

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas
Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

A widespread global outbreak of Hepatitis A virus (HAV) has prompted regulations in a few cities in the United States (US) mandating HAV vaccination of food service workers. This Viewpoint considers the global impact of HAV, analyzes ethical issues pertinent to recent mandatory vaccination regulations and the core values of public health. It explores the health and rights of stakeholders and ethical criteria for mandatory vaccination that could be applied globally with the ethical codes of the World Health Organization and the American Public Health Association. The goal is to help create ethical guidance for determining under what conditions, and for what populations, should regulations be created requiring vaccination for a communicable disease [10].

Africa and Eastern Mediterranean were the regions with higher HAV prevalence values. This study showed a high heterogeneity ($I2 > 75\%$) with a significant publication bias (p value Egger test < 0.001). The results of this review suggest that water matrices could be an important route of HAV transmission even in industrialized countries, despite the lower prevalence compared to less industrialized countries, and the availability of advanced water management systems. More effective water/wastewater treatment strategies are needed in developing countries to limit the environmental circulation of HAV[4].

Hepatitis A virus (HAV) infection is a common cause of acute viral hepatitis worldwide. Despite decades of research, the pathogenic mechanisms of hepatitis A remain incompletely understood. As the replication of HAV is noncytopathic in vitro, a widely accepted concept has been that virus-specific cytotoxic T cells are responsible for liver injury. However, accumulating evidence suggests that natural killer (NK) cells, NKT cells, and even non-HAV-specific $CD8^+$ T cells contribute to liver damage during HAV infection. In addition, intrinsic death of virus-infected hepatocytes has been implicated as a cause of liver injury in a murine model of hepatitis A. Furthermore, genetic variations in host factors such as T cell immunoglobulin-1 (TIM1) and IL-18 binding protein (IL-18BP) have been linked to hepatitis A severity. This review summarizes the current

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

knowledge of the mechanisms of hepatocellular injury in hepatitis A. Different mechanisms may be involved under different conditions and they are not necessarily mutually exclusive. A better understanding of these mechanisms would aid in diagnosis and treatment of diseases associated with HAV infection [12].

Hepatitis A virus (HAV) is one of the well-known viruses that cause hepatitis all around the globe. Although this illness has decreased in developed countries due to extensive immunization, numerous developing and under-developed countries are struggling with this virus. HAV infection can be spread by oral-fecal contact, and there are frequent epidemics through nutrition. Improvements in socioeconomic and sanitary circumstances have caused a shift in the disease's prevalence worldwide. Younger children are usually asymptomatic, but as they become older, the infection symptoms begin to appear. Symptoms range from slight inflammation and jaundice to acute liver failure in older individuals. While an acute infection may be self-limiting, unrecognized persistent infections, and the misapplication of therapeutic methods based on clinical guidelines are linked to a higher incidence of cirrhosis, hepatocellular carcinoma, and mortality. Fortunately, most patients recover within two months of infection, though 10-15% of patients will relapse within the first six months. A virus seldom leads to persistent infection or liver damage. The mainstay of therapy is based on supportive care. All children from 12-23 months, as well as some susceptible populations, should receive routine vaccinations, according to the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Laboratory diagnosis of HAV is based on antigen detection, checking liver enzyme levels, and antibody screening. Furthermore, polymerase chain reaction (PCR) technology has identified HAV in suspected nutrition sources; therefore, this technique is used for preventative measures and food-related laws [6].

Disease outbreaks resembling hepatitis A have been known since antiquity. However, it was not until World War II when two forms of viral hepatitis were

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas
Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

clearly differentiated. After the discovery of Australia antigen and its association with hepatitis B, similar methodologies were used to find the hepatitis A virus. The virus was ultimately identified when investigators changed the focus of their search from serum to feces and applied appropriate technology [7].

Hepatitis A virus (HAV) infections continue to represent a significant disease burden causing approximately 200 million infections, 30 million symptomatic illnesses and 30,000 deaths each year. Effective and safe hepatitis A vaccines have been available since the early 1990s. Initially developed for individual prophylaxis, HAV vaccines are now increasingly used to control hepatitis A in endemic areas. The human enteral HAV is eradicable in principle, however, HAV eradication is currently not being pursued. Inactivated HAV vaccines are safe and, after two doses, elicit seroprotection in healthy children, adolescents, and young adults for an estimated 30-40 years, if not lifelong, with no need for a later second booster. The long-term effects of the single-dose live-attenuated HAV vaccines are less well documented but available data suggest they are safe and provide long-lasting immunity and protection. A universal mass vaccination strategy (UMV) based on two doses of inactivated vaccine is commonly implemented in endemic countries and eliminates clinical hepatitis A disease in toddlers within a few years. Consequently, older age groups also benefit due to the herd protection effects. Single-dose UMV programs have shown promising outcomes but need to be monitored for many more years in order to document an effective immune memory persistence. In non-endemic countries, prevention efforts need to focus on 'new' risk groups, such as men having sex with men, prisoners, the homeless, and families visiting friends and relatives in endemic countries. This narrative review presents the current evidence regarding the immunological and epidemiological long-term effects of the hepatitis A vaccination and finally discusses emerging issues and areas for research [9].

Hepatitis A Virus (HAV) is a significant threat in terms of food safety. A systematic literature search with the research question "What are the clinical

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)

ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

outcomes of foodborne Hepatitis A virus infections?" was conducted. The pooled estimate of the outcomes-mortality, hospitalization, and severity rates, along with a 95% confidence interval (CI), was estimated. After screening, 33 studies were included for the data extraction and meta-analysis. The pooled prevalence of hospitalization among the HAV-positive patients was estimated to be 32% (95% CI 21-44), with high heterogeneity ($I^2 = 98\%$, $p < 0.01$). Australia had the highest hospitalization rate, with 82%, followed by Europe (42%). The hospitalization rate showed a significantly increasing trend (beta = 0.015, p=0.002) over the period. The pooled prevalence of mortality among the HAV-positive patients was estimated to be <1%, with low heterogeneity ($I^2 = 5\%$, $p = 0.39$). A wide range of food products were linked with the HAV outbreaks [11].

Viral hepatitis is characterized as an acute or chronic inflammation of the liver induced by an infection with certain viruses. At present, around 325 million humans suffer from the chronic form of the disease worldwide. Each year, about 1.6 million people die as a result of viral hepatitis. The causative agents, hepatitis viruses, are subdivided into five groups of pathogens, which are denoted with the letters A to E (HAV to HEV). These differ from each other with respect to phylogeny, transmission, epidemiology, host-specificity, life cycle, structure, and distinct aspects of pathogenesis.The strictly human-pathogenic HAV, a member of the Picornaviridae family, mostly induces acute hepatitis and displays a dominant spread over the Global South. The Hepeviridae-affiliated HEV shows a similar epidemiology, yet spreads further into industrialized countries due to its zoonotic potential. Furthermore, HEV is defined by the capability of inducing chronic hepatitis. This course of disease is also found in a more pronounced manner for the globally prevalent HBV (Hepadnaviridae) and its satellite virus HDV (Kolmioviridae), which further increases their carcinogenic potential. Lastly, a worldwide distribution is similarly described for HCV (Flaviviridae), which displays a high risk of chronifications and therefore a highly increased carcinogenic potential.The aforementioned pathogens differ with respect to their

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

properties and life cycles. Thus, a differentiated look on epidemiology, diagnostic procedures, and disease prevention is required. Despite the presence of therapies, in some cases even a vaccine, there is an urgent need for advances in research on these aspects, especially for poverty-related pathogens [5].

Conclusion

In conclusion, the findings of the study demonstrate that the spread of hepatitis A in Karakalpakstan is predominantly influenced by contaminated drinking water sources, inadequate sanitation systems, poor personal hygiene practices, and overcrowded living conditions. Seasonal patterns of morbidity were also identified, indicating an increase in cases during periods associated with higher water consumption and reduced water quality. Additionally, limited access to safe water supply and insufficient public awareness regarding transmission routes play a critical role in maintaining the endemic nature of the infection.The analysis further revealed that children and adolescents constitute the most vulnerable population groups, which is consistent with the fecal–oral mechanism of transmission characteristic of hepatitis A. The persistence of risk factors highlights gaps in preventive strategies and underscores the need for an integrated approach to disease control. Existing preventive measures, while partially effective, remain fragmented and insufficient to significantly reduce incidence rates without comprehensive reinforcement. Based on the results, the study emphasizes that effective prevention of viral hepatitis A requires a multifaceted strategy combining improvements in water supply systems, sanitation infrastructure, and waste management, along with systematic health education programs. Strengthening epidemiological surveillance, timely outbreak detection, and expansion of vaccination coverage—especially among high-risk groups—are essential components of sustainable prevention. Moreover, intersectoral cooperation between healthcare, environmental, and municipal services is crucial to address the underlying determinants of infection spread.

Eureka Open Access Journals
Open Access | Peer Reviewed | International Journals | Multidisciplinary Areas

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

References

1. Langan RC, Goodbred AJ. Hepatitis A. Am Fam Physician. 2021 Oct 1;104(4):368-374. PMID: 34652109.
2. Migueres M, Lhomme S, Izopet J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses. 2021 Sep 22;13(10):1900. doi: 10.3390/v13101900. PMID: 34696330; PMCID: PMC8540458.
3. Pintó RM, Pérez-Rodríguez FJ, Costafreda MI, Chavarria-Miró G, Guix S, Ribes E, Bosch A. Pathogenicity and virulence of hepatitis A virus. Virulence. 2021 Dec;12(1):1174-1185. doi: 10.1080/21505594.2021.1910442. PMID: 33843464; PMCID: PMC8043188.
4. Takuissu GR, Kenmoe S, Ebogo-Belobo JT, Kengne-Ndé C, Mbaga DS, Bowo-Ngandji A, Ndzie Ondigui JL, Kenfack-Momo R, Tchatchouang S, Kenfack-Zanguim J, Lontuo Fogang R, Zeuko'o Menkem E, Kame-Ngasse GI, Magoudjou-Pekam JN, Veneri C, Mancini P, Bonanno Ferraro G, Iaconelli M, Orlandi L, Del Giudice C, Suffredini E, La Rosa G. Occurrence of Hepatitis A Virus in Water Matrices: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2023 Jan 6;20(2):1054. doi: 10.3390/ijerph20021054. PMID: 36673812; PMCID: PMC9859052.
5. Bender D, Glitscher M, Hildt E. Die Virushepatitiden A bis E: Prävalenz, Erregermerkmale und Pathogenese [Viral hepatitis A to E: prevalence, pathogen characteristics, and pathogenesis]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Feb;65(2):139-148. German. doi: 10.1007/s00103-021-03472-0. Epub 2021 Dec 21. PMID: 34932130; PMCID: PMC8813840.
6. Gholizadeh O, Akbarzadeh S, Ghazanfari Hashemi M, Gholami M, Amini P, Yekanipour Z, Tabatabaie R, Yasamineh S, Hosseini P, Poortahmasebi V. Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms,

Eureka Journal of Health Sciences & Medical Innovation (EJHSMI)
ISSN 2760-4942 (Online) Volume 2, Issue 1, January 2026

https://eurekaoa.com/index.php/5

Diagnosis Error, and Vaccination. Can J Infect Dis Med Microbiol. 2023 Jan 4;2023:4263309. doi: 10.1155/2023/4263309. PMID: 36644336; PMCID: PMC9833905.

7. Feinstone SM. History of the Discovery of Hepatitis A Virus. Cold Spring Harb Perspect Med. 2019 May 1;9(5):a031740. doi: 10.1101/cshperspect.a031740. PMID: 29712682; PMCID: PMC6496330.
8. Lu M, Liu Y, Li L, Liu X, Wu B, Wu Y. Hepatitis Vaccines: Recent Advances and Challenges. Vaccines (Basel). 2025 Nov 20;13(11):1174. doi: 10.3390/vaccines13111174. PMID: 41295547; PMCID: PMC12656939.
9. Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Hum Vaccin Immunother. 2021 May 4;17(5):1496-1519. doi: 10.1080/21645515.2020.1819742. Epub 2020 Dec 16. PMID: 33325760; PMCID: PMC8078665.
10. Fleetwood J. Ethical considerations for mandating food worker vaccination during outbreaks: an analysis of hepatitis A vaccine. J Public Health Policy. 2021 Sep;42(3):465-476. doi: 10.1057/s41271-021-00293-y. Epub 2021 Jun 29. PMID: 34188176; PMCID: PMC8239318.
11. Gandhi AP, Al-Mohaithef M, Aparnavi P, Bansal M, Satapathy P, Kukreti N, Rustagi S, Khatib MN, Gaidhane S, Zahiruddin QS. Global outbreaks of foodborne hepatitis A: Systematic review and meta-analysis. Heliyon. 2024 Mar 29;10(7):e28810. doi: 10.1016/j.heliyon.2024.e28810. PMID: 38596114; PMCID: PMC11002584.
12. Wang M, Feng Z. Mechanisms of Hepatocellular Injury in Hepatitis A. Viruses. 2021 May 8;13(5):861. doi: 10.3390/v13050861. PMID: 34066709; PMCID: PMC8151331.